Skip to main content
PMC home page
Cytotechnology logoLink to Cytotechnology
. 1998 Sep;27(1-3):283–292. doi: 10.1023/A:1008053913764

The role of oncogenes in drug resistance

Dihua Yu 1
PMCID: PMC3449565  PMID: 19002799

Abstract

Increasing evidences indicate that oncogenes can directly or indirectly impact on cancer-cell drug resistance. This chapter provides a conceptual review regarding the role of oncogenes in drug resistance. The review is focused on drug resistance mediated by oncogenes encoding growth factor receptors, signaling molecules, transcription factors, cell-cycle regulators, and apoptosis regulators. It is my hope that better undertsnading on the role of oncogenes in drug resistance will invoke ideas on new approaches to enhance the cytotoxicity of the standard chemotherapeutic agents by functional perturbation of resistance-inducing oncogenes.

Keywords: apoptosis, cell-cycle control, Growth factor receptors, signal transduction, transcription factors

Full Text

The Full Text of this article is available as a PDF (79.3 KB).

References

  1. Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst. 1988;80:1605–1611. doi: 10.1093/jnci/80.20.1605. [DOI] [PubMed] [Google Scholar]
  2. Aggarwal BB, Totpal K, Ali-Osman F, Budde RJ, Pocsik E. pp60v-src kinase overexpression leads to cellular resistance to the antiproliferative effects of tumor necrosis factor. FEBS Letters. 1994;345:219–224. doi: 10.1016/0014-5793(94)00441-2. [DOI] [PubMed] [Google Scholar]
  3. Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver LK, Hurd SD, Stewart SJ. p185c-erbB-2 signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res. 1994;54:3758–3765. [PubMed] [Google Scholar]
  4. Bargmann CI, Hung M-C, Weinberg RA. The neuoncogene encodes an epidermal growth factor receptor-related protein. Nature. 1986;319:226–230. doi: 10.1038/319226a0. [DOI] [PubMed] [Google Scholar]
  5. Bartkova J, Lukas J, Muller H, Strauss M, Gusterson B, Bartek J. Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Research. 1995;55:949–56. [PubMed] [Google Scholar]
  6. Bates S, Peters G. Cyclin D1 as a cellular proto-oncogene. Seminars in Cancer Biology. 1995;6:73–82. doi: 10.1006/scbi.1995.0010. [DOI] [PubMed] [Google Scholar]
  7. Begleiter A, Mowat M, Israels LG, Johnston JB. Chlorambucil in chronic lymphocytic leukemia: mechanism of action. Leukemia and Lymphoma. 1996;23:187–201. doi: 10.3109/10428199609054821. [DOI] [PubMed] [Google Scholar]
  8. Bhushan A, Abramson R, Chiu JF, Tritton TR. Expression of c-fos in human and murine multidrug-resistant cells. Mol Pharm. 1992;t42:69–74. [PubMed] [Google Scholar]
  9. Carraway KL, Sliwkowski MX, Akita R, Platko JV, Guy PM, Nuijens A, Diamonti J, Vandelen RL, Cantley LC, Cerione RA. The erbB-3 gene product is a receptor for heregulin. J Biol Chem. 1994;269:14303–14306. [PubMed] [Google Scholar]
  10. Chang T, Khalsa O, Wang H, Lee ME, Schlegel R. Staurosporine resistance accompanies DNA tumor virus-induced immortalization and is independent of the expression and activities of ERK1, ERK2, cyclin A, cyclin-dependent kinase (cdk)2, and cdk4. Cell Growth and Diff. 1996;7:361–372. [PubMed] [Google Scholar]
  11. Chevalier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA, Van Glabbeke M. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase 2 trial of the clinical screening cooperative group of the European Organization for Research and Treatment of Cancer. J of Clin Oncol. 1995;13:314–322. doi: 10.1200/JCO.1995.13.2.314. [DOI] [PubMed] [Google Scholar]
  12. Chrysogelos SA, Dickson RB. EGF receptor expression, regulation, and function in breast cancer. Breast Cancer Res and Treatment. 1994;29:29–40. doi: 10.1007/BF00666179. [DOI] [PubMed] [Google Scholar]
  13. Coussens L, Yang-Feng TL, Liao Y-C, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, Levinson A, Ullrich A. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neuoncogene. Science. 1985;230:1132–1139. doi: 10.1126/science.2999974. [DOI] [PubMed] [Google Scholar]
  14. Dickstein B, Valverius EM, Wosikowski K, Saceda M, Pearson JW and Martin MB et al. (1993) Increased epidermal growth factor receptor in an estrogen-responsive, adriamycin-resistant MCF-7 cell line. J Cell Physiol 157. [DOI] [PubMed]
  15. Dixit M, Yang JL, Poirier MC, Price JO, Andrews PA, Arteaga CL. Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal grwoth factor antisense RNA. J Natl Cancer Inst. 1997;89:365–373. doi: 10.1093/jnci/89.5.365. [DOI] [PubMed] [Google Scholar]
  16. Fan Z, Baselga B, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well-established A431 cell xenografts. Cancer Res. 1993;53:4637–4642. [PubMed] [Google Scholar]
  17. Gillett C, Fanti V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D and Peters G (1994) Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54. [PubMed]
  18. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. The EMBO Journal. 1997;16:1647–1655. doi: 10.1093/emboj/16.7.1647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam C-M, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Burki K, Castiglione M, Collins J, Lindtner J, Senn H-J, Ludwig IBCSG. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol. 1992;10:1049–1056. doi: 10.1200/JCO.1992.10.7.1049. [DOI] [PubMed] [Google Scholar]
  20. Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP, Shawver LK. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res. 1991;51:4575–4580. [PubMed] [Google Scholar]
  21. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Critical Reviews in Biochemistry and Molecular Biology. 1995;30:445–600. doi: 10.3109/10409239509083491. [DOI] [PubMed] [Google Scholar]
  22. Hill ME, MacLennan KA, Cunningham DC, Vaughan-Hudson B, Burke M, Clarke P, Di Stefano F, Anderson L, Vaughan-Hudson G, Mason D, Selby P, Linch DC. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Blood. 1996;88:1046–1051. [PubMed] [Google Scholar]
  23. Hochhauser D, Schnieders B, Ercikan-Abali E, Gorlick R, Muise-Helmericks R, Li WW, Fan J, Banerjee D, Bertino JR. Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line. Journal of the National Cancer Institute. 1996;88:1269–1275. doi: 10.1093/jnci/88.18.1269. [DOI] [PubMed] [Google Scholar]
  24. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochodrial membrane protein that blocks programmed cell death. Nature. 1990;348:334–336. doi: 10.1038/348334a0. [DOI] [PubMed] [Google Scholar]
  25. Hockenbery DM, Oltvai ZN, Yin X-M, Milliman C, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell. 1993;75:241–251. doi: 10.1016/0092-8674(93)80066-N. [DOI] [PubMed] [Google Scholar]
  26. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN. Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991;83:1797–1805. doi: 10.1093/jnci/83.24.1797-a. [DOI] [PubMed] [Google Scholar]
  27. Huang Y, Ibrado AM, Reed JC, Bullock G, Ray S, Tang C, Bhalla K. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia. 1997;11:253–257. doi: 10.1038/sj.leu.2400557. [DOI] [PubMed] [Google Scholar]
  28. Jacquemier J, Penault-Llorca F, Viens P, Houvenaeghel G, Hassoun J, Torrente M, Adelaide J, Birnbaum D. Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression. Anticancer Res. 1994;14:2773–2778. [PubMed] [Google Scholar]
  29. Kitada S, Takayama S, De Riel K, Tanaka S, Reed JC. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Research and Development. 1994;4:71–79. doi: 10.1089/ard.1994.4.71. [DOI] [PubMed] [Google Scholar]
  30. Kopnin BP, Stromskaya TP, Kondratov RV, Ossovskaya VS, Pugacheva EN, Rybalkina EY, Khokhlova OA, Chumakov PM. Influence of exogenous ras and p53 on P-glycoprotein function in immortalized rodent fibroblasts. Oncology Research. 1995;7:299–306. [PubMed] [Google Scholar]
  31. Livingstone A, Mairs RJ. N-myc amplification and its relationship to experimental therapy. Journal of Neuro-Oncology. 1997;31:33–39. doi: 10.1023/A:1005773011779. [DOI] [PubMed] [Google Scholar]
  32. Marx J. Oncogenes reach a milestone. Science. 1994;266:1942–1944. doi: 10.1126/science.7801118. [DOI] [PubMed] [Google Scholar]
  33. Masumoto N, Nakano S. Cell signaling and CDDP resistance. Japanese Journal of Cancer and Chemotherapy. 1997;24:424–430. [PubMed] [Google Scholar]
  34. Mendelsohn J, Fan Z. Epidermal Growth Factor Receptor Family and Chemosensitization. J Natl Cancer Inst. 1997;89:341–343. doi: 10.1093/jnci/89.5.341. [DOI] [PubMed] [Google Scholar]
  35. Mizutani Y, Fukumoto M, Bonavida B, Yoshida O. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide. Cancer. 1994;74:2546–2554. doi: 10.1002/1097-0142(19941101)74:9<2546::AID-CNCR2820740924>3.0.CO;2-Y. [DOI] [PubMed] [Google Scholar]
  36. Moffat GJ, McLaren AW, Wolf CR. Involvement of Jun and Fos proteins in regulating transcriptional activation of the human pi class glutathione S-transferase gene in multidrug-resistant MCF7 breast cancer cells. J Biol Chem. 1994;269:16397–16402. [PubMed] [Google Scholar]
  37. Morabito F, Filangeri M, Callea I, Sculli G, Callea V, Fracchiolla NS, Neri A, Brugiatelli M. Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs. Haematologica. 1997;82:16–20. [PubMed] [Google Scholar]
  38. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC. C-erbB-2 expression and response to adjuvant therapy in woman with node-positive early breast cancer. N Engl J Med. 1994;330:1260–1266. doi: 10.1056/NEJM199405053301802. [DOI] [PubMed] [Google Scholar]
  39. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, Haber M. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med. 1996;334:231–238. doi: 10.1056/NEJM199601253340405. [DOI] [PubMed] [Google Scholar]
  40. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast cancer and ovarian cancer cells. Oncogene. 1994;9:1829–1838. [PubMed] [Google Scholar]
  41. Plowman GD, Grenn JM, Culouscou J-M, Carlton GW, Rothwell VM, Buckley S. Heregulin induces tyrosine phosphorylation of HER4/p180erbB-4. Nature. 1993;366:473–475. doi: 10.1038/366473a0. [DOI] [PubMed] [Google Scholar]
  42. Ransone LJ, Verma IM. Nuclear proto-oncogenes fos and jun. Annu Rev Cell Biol. 1990;6:539–557. doi: 10.1146/annurev.cb.06.110190.002543. [DOI] [PubMed] [Google Scholar]
  43. Reed JC. Bcl-2: preventino of apoptosis as a mechanism of drug resistance. Hematology - Oncology Clinics of North America. 1995;9:451–473. [PubMed] [Google Scholar]
  44. Reeve JG, Xiong J, Morgan J, Bleehen NM. Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. British J of Cancer. 1996;73:1193–1200. doi: 10.1038/bjc.1996.230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Riva C, el Khyari S, Rustum Y, Barra Y. Resistance to cytosine arabinoside in cells transfected with activated Ha-ras oncogene. Anticancer Research. 1995;15:1297–1302. [PubMed] [Google Scholar]
  46. Riva-Lavieille C. Drug resistance, oncogenes and antioncogenes in epithelial tumors. Bulletin du Cancer. 1994;81:105s–111s. [PubMed] [Google Scholar]
  47. Scanlon KJ, Ishida H, Kashani-Sabet M. Ribozyme-mediated reversal of the multidrug-resistant phenotype. Proceedings of the National Academy of Sciences of the United States of America. 1994;91:11123–11127. doi: 10.1073/pnas.91.23.11123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Schechter AL, Hung M-C, Vaidyanathan L, Weinberg RA, Yang-Feng TL, Francke U, Ullrich A, Coussens L. The neugene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science. 1985;229:976–978. doi: 10.1126/science.2992090. [DOI] [PubMed] [Google Scholar]
  49. Sepp-Lorenzino L, Bos M, Ma Z, Baselga J, Rands E, Kohl NE, et al. Farnesyl protein transferase inhibitors (FITs) block tyrosine kinase signal transduction and act in concert with an anti-EGF receptor antibody to inhibit cancer cell growth (Abstract) Proc Am Assoc Cancer Res. 1996;37:421. [Google Scholar]
  50. Sklar MD, Prochownik EV. Modulation of cis-platinum resistance in Friend erythroleukemia cells by c-myc. Cancer Research. 1991;51:2118–2123. [PubMed] [Google Scholar]
  51. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neuoncogene. Science. 1987;235:177–182. doi: 10.1126/science.3798106. [DOI] [PubMed] [Google Scholar]
  52. Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A, Fendly BM, Cerione RA, Vandlen RL, Carraway KL. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem. 1994;269:14661–14665. [PubMed] [Google Scholar]
  53. Stoetzer OJ, Nussler V, Darsow M, Gullis E, Pelka-Fleischer R, Scheel U, Wilmanns W. Association of bcl-2, bax, bclxL and interleukin-1 beta-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. Leukemia. 1996;10(Suppl3):S18–S22. [PubMed] [Google Scholar]
  54. Tang C, Willingham MC, Reed JC, Miyashita T, Ray S, Ponnathpur V, Huang Y, Mahoney ME, Bullock G, Bhalla K. High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia. 1994;8:1960–1969. [PubMed] [Google Scholar]
  55. Tanio Y. Relationship between drug resistance and oncogenes in lung cancer cell lines. Nippon Kyobu Shikkan Gakkai Zasshi - Japanese Journal of Thoracic Diseases. 1992;30:42–47. [PubMed] [Google Scholar]
  56. Teixeira C, Reed JC, Pratt MA. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Research. 1995;55:3902–3907. [PubMed] [Google Scholar]
  57. Tetu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer. 1994;73:2359–65. doi: 10.1002/1097-0142(19940501)73:9<2359::aid-cncr2820730919>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  58. Theodorescu D, Connors KM, Groce A, Hoffman RM, Kerbel RS. Lack of influence of c-Ha-ras expression on the drug sensitivity of human bladder cancer histocultured in three-dimensions. Anticancer Research. 1993;13:941–946. [PubMed] [Google Scholar]
  59. Tsai C-M, Chang K-T, Perng R-P, Mitsudomi T, Chen M-H, Kadoyama C, Gazdar AF. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neugene expression but not with rasgene mutation. J Natl Cancer Inst. 1993;85:897–901. doi: 10.1093/jnci/85.11.897. [DOI] [PubMed] [Google Scholar]
  60. Tsai C-M, Yu D, Chang K-T, Wu L-H, Perng PR-P, Ibrahim NK, Hung M-C. Enhanced chemoresistance by elevation of p185neu levels in HER-2/neutransfected human lung cancer cells. J Natl Cancer Inst. 1995;87:682–684. doi: 10.1093/jnci/87.9.682. [DOI] [PubMed] [Google Scholar]
  61. Tsai CM, Levitzki A, Wu L-H, Chang KT, Chen C-C, Gazit A, Perng RP. Enhancement of chemosensitivity by tyrphostin AG825 in high-p185neu expressing non-small cell lung cancer cells. Cancer Res. 1996;56:1068–1074. [PubMed] [Google Scholar]
  62. Van Waardenburg RC, Prins J, Meijer C, Uges DR, De Vries EG, Mulder NH. Effects of c-myc oncogene modulation on drug resistance in human small cell lung carcinoma cell lines. Anticancer Research. 1996;16:1963–1970. [PubMed] [Google Scholar]
  63. Vickers PJ, Dickson RB, Shoemaker R, Cowan KH. A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol Endocrinol. 1988;2:886–892. doi: 10.1210/mend-2-10-886. [DOI] [PubMed] [Google Scholar]
  64. Walker A, Taylor ST, Hickman JA, Dive C. Germinal center-derived signals act with Bcl-2 to decrease apoptosis and increase clonogenicity of drug-treated human B lymphoma cells. Cancer Research. 1997;57:1939–1945. [PubMed] [Google Scholar]
  65. Wall ME, Wani MC. Camptothecin and Taxol: Discovery to Clinic - Thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 1995;55:753–760. [PubMed] [Google Scholar]
  66. Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO Journal. 1995;14:4267–4275. doi: 10.1002/j.1460-2075.1995.tb00101.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus Brevifolia. J Am Chem Soc. 1971;93:2325–2327. doi: 10.1021/ja00738a045. [DOI] [PubMed] [Google Scholar]
  68. Wilson WH, Teruya-Feldstein J, Fest T, Harris C, Steinberg SM, Jaffe ES, Raffeld M. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood. 1997;89:601–609. [PubMed] [Google Scholar]
  69. Wood DP, Jr, Anderson AE, Fair R, Chaganti RS. Ras oncogene point mutations in bladder cancer resistant to cisplatin. Urological Research. 1992;20:313–316. doi: 10.1007/BF00300267. [DOI] [PubMed] [Google Scholar]
  70. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K. Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor. Nature. 1986;319:230–234. doi: 10.1038/319230a0. [DOI] [PubMed] [Google Scholar]
  71. Yamazaki H, Schneider E, Myers CE, Sinha BK. Oncogene overexpression and de novo drug-resistance in human prostate cancer cells. Biochimica et Biophysica Acta. 1994;1226:89–96. doi: 10.1016/0925-4439(94)90063-9. [DOI] [PubMed] [Google Scholar]
  72. Yarden Y, Weinberg RA. Experimental approaches to hypothetical hormones: detection of a candidate ligand of the neu protooncogene. Proc Natl Acad Sci USA. 1989;86:3179–3183. doi: 10.1073/pnas.86.9.3179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Yu D, Liu B, Sun D, Jing T, Price JE, Singletary SE, Hortobagyi GN, Hung MC. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to Taxol. Oncogene. 1998;16:2087–2094. doi: 10.1038/sj.onc.1201729. [DOI] [PubMed] [Google Scholar]
  74. Yu D, Liu B, Tan M, Li J, Wang S-S, Hung M-C. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene. 1996;13:1359–1365. [PubMed] [Google Scholar]
  75. Zhang L, Hung M-C. Sensitization of HER-2/neuoverexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tryosine kinase inhibitor emodin. Oncogene. 1996;12:571–576. [PubMed] [Google Scholar]

Articles from Cytotechnology are provided here courtesy of Springer Science+Business Media B.V.

RESOURCES